/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Lisata Therapeutics Inc Share Price Today: Live Updates & Key Insights

Lisata Therapeutics Inc share price today is $5.03, up 0%. The stock opened at $5.03 against the previous close of $5.03, with an intraday high of $5.03 and low of $5.02.

Lisata Therapeutics Inc Share Price Chart

style
pb-0

Lisata Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Lisata Therapeutics Inc Share Price Performance

$5.03 0(0%) LSTA at 13 Mar 2026 02:02 PM Biotechnology
Lowest Today 5.02
Highest Today 5.03
Today’s Open 5.03
Prev. Close 5.03
52 Week High 5.07
52 Week Low 1.81
Day’s Range: Low 5.02 High 5.03
52-Week Range: Low 1.81 High 5.07
1 day return -
1 Week return +20.09
1 month return +9.6
3 month return +143.68
6 month return +125.11
1 year return +124.1
3 year return +52.12
5 year return -84.21
10 year return -

Lisata Therapeutics Inc Institutional Holdings

Vanguard Group Inc 3.07

Vanguard Total Stock Mkt Idx Inv 2.17

Renaissance Technologies Corp 1.40

BML Capital Management LLC 0.83

Geode Capital Management, LLC 0.72

BlackRock Inc 0.62

Vanguard Institutional Extnd Mkt Idx Tr 0.55

Ground Swell Capital, LLC 0.44

Fidelity Extended Market Index 0.43

State Street Corp 0.16

Dimensional Fund Advisors, Inc. 0.16

HPM Partners LLC 0.14

XTX Topco Ltd 0.13

Bank of America Corp 0.12

Northern Trust Corp 0.12

HighTower Advisors, LLC 0.11

Fidelity Series Total Market Index 0.10

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Spartan Extended Market Index Pool F 0.08

Royal Bank of Canada 0.07

Spartan Total Market Index Pool G 0.05

Fidelity Total Market Index 0.05

Vanguard Instl Ttl Stck Mkt Idx Tr 0.05

Dimensional US Equity Market ETF 0.04

DFA US Core Equity Class F 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

DFA US Social Core Equity 2 Portfolio 0.02

Fidelity Nasdaq Composite Index 0.02

Founders Capital Management Inc 0.02

Tower Research Capital LLC 0.02

Vanguard U.S. Eq Idx £ Acc 0.01

Connective Capital Management LLC 0.01

DFA US Vector Equity Class F 0.01

State St US Ttl Mkt Indx NL Cl A 0.00

Morgan Stanley - Brokerage Accounts 0.00

Advisor Group Holdings, Inc. 0.00

SBI Securities Co Ltd 0.00

Lisata Therapeutics Inc Market Status

Strong Buy: 1

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Lisata Therapeutics Inc Fundamentals

Market Cap 44.37 M

PB Ratio 2.5539

PE Ratio 0.0

Enterprise Value 22.45 M

Total Assets 35.00 M

Volume 58517

Lisata Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:121372000 121.4M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:63771000 63.8M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-21465000 -21.5M, FY22:-54225000 -54.2M, FY21:-27466000 -27.5M, FY20:-8141000 -8.1M, FY19:-20101000 -20.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:70000 0.1M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:70000 0.1M, Q1/2025:-43000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-45000 -0.0M

Quarterly Net worth Q3/2025:-4249000 -4.2M, Q2/2025:-4659000 -4.7M, Q1/2025:-4724000 -4.7M, Q3/2024:-4930000 -4.9M, Q2/2024:-5044000 -5.0M

About Lisata Therapeutics Inc & investment objective

Company Information Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Organisation Biotechnology

Employees 26

Industry Biotechnology

CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow